What postoperative euglycemic protocol should be used for adult patients after cardiac surgery?

Cardiac Postoperative Euglycemic Protocol

After cardiac surgery, maintain intravenous insulin infusion until blood glucose is stable ≤180 mg/dL (10 mmol/L), then transition to a basal-bolus subcutaneous insulin regimen at oral feeding resumption, targeting glucose levels of 110-180 mg/dL to reduce postoperative complications while avoiding hypoglycemia. 1, 2

Intravenous Insulin Phase

Target Range and Duration

• Continue IV insulin infusion until blood glucose levels are stable and ≤180 mg/dL (10 mmol/L) 1, 2
• Maintain infusion for at least 24 hours with stable glucose levels before transitioning 1
• If insulin infusion rate is ≥5 IU/h, this indicates major insulin resistance—keep the IV infusion in place longer 1
• If infusion rate is ≤0.5 IU/h, you can safely discontinue the IV insulin 1

Evidence Supporting This Approach

The 2019 ERAS Society cardiac surgery guidelines recommend treating hyperglycemia >160-180 mg/dL with insulin infusion, though they note more cardiac-specific studies are needed 2. Recent research demonstrates that combining IV insulin with subcutaneous glargine achieves superior glycemic control (mean 9.25 vs 12.14 mmol/L) and reduces acute kidney injury (2.3% vs 23.1%) and sternal wound infections (0.8% vs 13.1%) compared to IV insulin alone 3.

Transition to Subcutaneous Insulin

Timing

• Transition at resumption of oral feeding 1
• Administer the first dose of long-acting (basal) insulin immediately after stopping the IV infusion—do not allow a gap 1
• Optimal timing for basal insulin injection is 20:00 hours 1
• If transitioning before 20:00 hours, give an adjusted dose immediately, then give the full dose again at 20:00 hours 1

Dosing Calculations

The basal-bolus scheme is mandatory as it significantly improves glycemic control and decreases postoperative complications compared to sliding-scale insulin 1

For patients on IV insulin ≥24 hours:

• Calculate total 24-hour IV insulin dose
• Give 50% as long-acting basal insulin (e.g., glargine) once daily 1
• Give 50% as ultra-rapid analogue (e.g., lispro, aspart) divided across meals 1
• Alternative approach: Give 80% of IV dose as basal insulin plus ultra-rapid analogue at first meal 1

For patients on IV insulin <24 hours (new-onset hyperglycemia):

• Start at 0.5-1 IU/kg total daily dose based on patient weight 1
• Split: 50% basal insulin, 50% ultra-rapid analogue across meals
• If meal is light, give only half the anticipated ultra-rapid dose 1

Prandial Insulin

• Administer ultra-rapid analogue at the first meal 1
• Adjust dose to carbohydrate content of each meal 1

Monitoring and Safety

Hypoglycemia Management

Critical thresholds requiring immediate action:

• <60 mg/dL (<3.3 mmol/L): Administer glucose immediately, even without symptoms 1
• 60-100 mg/dL (3.3-5.5 mmol/L) with symptoms: Give glucose 1

Route of administration:

• Conscious patients: Oral glucose preferred 1
• Unconscious or unable to swallow: IV glucose immediately, then oral when conscious 1

Important caveat: Hypoglycemia unawareness is common—scale up regular blood glucose monitoring in all patients on insulin 1

Hyperglycemia Management

For glucose >300 mg/dL (>16.5 mmol/L):

• In Type 1 diabetes or insulin-treated Type 2 diabetes: Check for ketosis systematically 1
• Without ketosis: Add ultra-rapid insulin analogue and ensure good hydration 1
• With ketosis: Suspect diabetic ketoacidosis, call physician immediately, start ultra-rapid insulin, consider ICU transfer 1

In Type 2 diabetes patients: Severe hyperglycemia may indicate hyperosmolar state (>320 mosmol/L)—check electrolytes urgently and transfer to ICU if confirmed 1

Special consideration for SGLT2 inhibitors: These medications are associated with a 54.8% incidence of postoperative ketoacidosis (often euglycemic) versus 10.1% in non-users—monitor ketones closely in these patients 4

Special Populations

Insulin Pump Users

• Reconnect personal pump only when patient is fully autonomous 1
• If not autonomous: Mandatory immediate transition to basal-bolus subcutaneous injections 1

Continuous Glucose Monitoring

Recent evidence shows CGM with specialized titration protocols improves time-in-range 70-180 mg/dL (83.8% vs 75.8%) and reduces postoperative atrial fibrillation (18.8% vs 55.6%) compared to point-of-care monitoring, while maintaining very low hypoglycemia rates 5

Key Clinical Pitfalls to Avoid

1. Never create a gap between stopping IV insulin and starting subcutaneous basal insulin—this causes dangerous hyperglycemic rebound 1

2. Do not use sliding-scale insulin alone—the basal-bolus regimen is superior for reducing complications 1

3. Avoid tight glucose targets (80-110 mg/dL)—these increase hypoglycemia risk without clear benefit; target 110-180 mg/dL instead 2, 6

4. Monitor for hyperosmolarity in Type 2 diabetes—clinical signs are deceptive (asthenia, confusion, dehydration) 1

5. Check ketones in SGLT2 inhibitor users—even with normal glucose levels 4

The evidence strongly supports moderate-intensity glycemic control (110-180 mg/dL) as it reduces infections by 56% and atrial fibrillation by 39% while maintaining low hypoglycemia rates (2-3%) 6. This balanced approach prioritizes both safety and efficacy in reducing postoperative morbidity.